Speech-Language Pathologists in Millinocket, ME Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Ms. Dorothy Louise Friel, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 199 State Street, Millinocket, ME 04462 Phone: 207-723-6430    Fax: 207-447-5699

Ann Sutherland Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 191 Granite St, Office Of Special Services, Millinocket, ME 04462 Phone: 207-723-6405

Mrs. Cynthia E Ingerson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 191 Granite St, Office Of Special Services, Millinocket, ME 04462 Phone: 207-723-6404

Mrs. Jane M. Bennett, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 899 Central St, Millinocket, ME 04462 Phone: 207-723-6450    Fax: 207-723-3008

News Archive

The House approves six health-related measures, including legislation related to the disposal of unused prescription drugs

The Hill's Healthwatch Blog: "The House passed six health-related bills Wednesday evening, including efforts to combat Medicare fraud and dispose of unused prescription drugs." The measures were approved under suspension of the rules, "an expedited procedure that only allows for 40 minutes of debate followed by a voice vote."

Canada's first prescription drug atlas maps billions in spending

Researchers at the University of British Columbia Centre for Health Services and Policy Research have developed a comprehensive portrait of pharmaceutical spending in Canada - more than $20 billion by the end of 2005 - and assembled the results into a first-of-its-kind atlas.

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

New ESE guidelines provide evidence-based recommendations for handling adrenal incidentalomas

The appropriate clinical response to adrenal incidentaloma should depend on the likelihood of malignancy, according to new guidelines published today by the European Society of Endocrinology, in collaboration with the European Network for the Study of Adrenal Tumours and first presented at ESE's annual European Congress of Endocrinology in May 2016.

Read more Medical News

› Verified 1 days ago